BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1610 related articles for article (PubMed ID: 28922692)

  • 1. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
    Chong J; Leung B; Poole P
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD002309. PubMed ID: 28922692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
    Chong J; Leung B; Poole P
    Cochrane Database Syst Rev; 2013 Nov; (11):CD002309. PubMed ID: 24190161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease.
    Janjua S; Fortescue R; Poole P
    Cochrane Database Syst Rev; 2020 May; 5(5):CD002309. PubMed ID: 32356609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
    Chong J; Poole P; Leung B; Black PN
    Cochrane Database Syst Rev; 2011 May; (5):CD002309. PubMed ID: 21563134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD).
    Ni H; Moe S; Soe Z; Myint KT; Viswanathan KN
    Cochrane Database Syst Rev; 2018 Dec; 12(12):CD011594. PubMed ID: 30536566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD).
    Ni H; Htet A; Moe S
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD011897. PubMed ID: 28631387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aclidinium bromide for stable chronic obstructive pulmonary disease.
    Ni H; Soe Z; Moe S
    Cochrane Database Syst Rev; 2014 Sep; 2014(9):CD010509. PubMed ID: 25234126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylactic antibiotics for adults with chronic obstructive pulmonary disease: a network meta-analysis.
    Janjua S; Mathioudakis AG; Fortescue R; Walker RA; Sharif S; Threapleton CJ; Dias S
    Cochrane Database Syst Rev; 2021 Jan; 1(1):CD013198. PubMed ID: 33448349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological interventions for the treatment of depression in chronic obstructive pulmonary disease.
    Pollok J; van Agteren JE; Carson-Chahhoud KV
    Cochrane Database Syst Rev; 2018 Dec; 12(12):CD012346. PubMed ID: 30566235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-acting beta2-agonists for chronic obstructive pulmonary disease.
    Kew KM; Mavergames C; Walters JA
    Cochrane Database Syst Rev; 2013 Oct; (10):CD010177. PubMed ID: 24127118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can roflumilast, a phosphodiesterase-4 inhibitor, improve clinical outcomes in patients with moderate-to-severe chronic obstructive pulmonary disease? A meta-analysis.
    Luo J; Wang K; Liu D; Liang BM; Liu CT
    Respir Res; 2016 Feb; 17():18. PubMed ID: 26887407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD).
    Herath SC; Normansell R; Maisey S; Poole P
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD009764. PubMed ID: 30376188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunostimulants versus placebo for preventing exacerbations in adults with chronic bronchitis or chronic obstructive pulmonary disease.
    Fraser A; Poole P
    Cochrane Database Syst Rev; 2022 Nov; 11(11):CD013343. PubMed ID: 36373977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interventions to improve adherence to pharmacological therapy for chronic obstructive pulmonary disease (COPD).
    Janjua S; Pike KC; Carr R; Coles A; Fortescue R; Batavia M
    Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013381. PubMed ID: 34496032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tiotropium versus placebo for chronic obstructive pulmonary disease.
    Karner C; Chong J; Poole P
    Cochrane Database Syst Rev; 2012 Jul; (7):CD009285. PubMed ID: 22786525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
    Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease.
    Calverley PM; Sanchez-Toril F; McIvor A; Teichmann P; Bredenbroeker D; Fabbri LM
    Am J Respir Crit Care Med; 2007 Jul; 176(2):154-61. PubMed ID: 17463412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD.
    Rennard SI; Calverley PM; Goehring UM; Bredenbröker D; Martinez FJ
    Respir Res; 2011 Jan; 12(1):18. PubMed ID: 21272339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease.
    Chong J; Karner C; Poole P
    Cochrane Database Syst Rev; 2012 Sep; 2012(9):CD009157. PubMed ID: 22972134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease.
    Cheyne L; Irvin-Sellers MJ; White J
    Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD009552. PubMed ID: 26391969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 81.